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E-mail address: geereddy@yahoo.com (G.B. ReddyAccumulation of intracellular sorbitol due to increased aldose reductase (ALR2) activity has been
implicated in the development of various secondary complications of diabetes. In this study we
show that curcumin inhibits ALR2 with an IC50 of 10 lM in a non-competitive manner, but is a poor
inhibitor of closely-related members of the aldo-keto reductase superfamily, particularly aldehyde
reductase. Results from molecular docking studies are consistent with the pattern of inhibition of
ALR2 by curcumin and its speciﬁcity. Moreover, curcumin is able to suppress sorbitol accumulation
in human erythrocytes under high glucose conditions, demonstrating an in vivo potential of curcu-
min to prevent sorbitol accumulation. These results suggest that curcumin holds promise as an
agent to prevent or treat diabetic complications.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Prolonged exposure to chronic hyperglycemia in diabetes can
lead to various complications, affecting the cardiovascular, renal,
neurological and visual systems [1]. Although mechanisms leading
to diabetic complications are not completely understood, many
biochemical pathways associated with hyperglycemia have been
implicated [1]. Among these, the polyol pathway has been exten-
sively studied [2]. Aldose reductase (ALR21 or AKR1B1; EC:
1.1.1.21) belongs to aldo-keto reductase (AKR) super family. It is
the ﬁrst and rate-limiting enzyme in the polyol pathway and re-
duces glucose to sorbitol utilizing NADPH as a cofactor. Sorbitol
is then metabolized to fructose by sorbitol dehydrogenase [2].
Accumulation of sorbitol leads to osmotic swelling, changes in
membrane permeability, and also oxidative stress culminating in
tissue injury [3].
A number of studies with experimental animals suggest that
inhibition of ALR2 could be effective in the prevention of some dia-chemical Societies. Published by E
aldehyde reductase; ALR2,
uman small intestine reduc-
ells
of Nutrition, Jamai-Osmania,
).betic complications including cataract, retinopathy, nephropathy
and neuropathy [3–5]. A number of ALR2 inhibitors (ARI), both
synthetic and natural, have been found to delay or substantially
prevent some diabetic complications in animal models and some
have been evaluated in clinical trials [5,6]. To date, most ARIs have
met with limited success, and some of the synthetic ARIs were
associated with deleterious side effects and poor penetration of
target tissues such as nerve and retina [5–8]. Largely, two chemical
classes of ARI have been tested in phase III trials. While carboxylic
acid inhibitors (zopolrestat, ponalrestat and tolerestat) have shown
poor tissue permeability and are not very potent in vivo, spiroi-
mide (spirohydantoin) inhibitors (sorbinil) penetrate tissues more
efﬁciently but many have been associated with skin reactions and
liver toxicity [3–6].
Aldehyde reductase (ALR1; EC: 1.1.1.2) is one of AKR family
members that is closely related to ALR2 and known to play a role
in the detoxiﬁcation of reactive aldehydes [9,10]. Since many ARIs
inhibit both ALR2 and ALR1 [9,10], it has been suggested that
poor selectivity might have contributed to the poor outcome of
ARI clinical trials [5]. Recently, other AKR members have been
identiﬁed that are similar to ALR2. One such AKR is human small
intestine reductase (HSIR or AKR1B10), which has 70–80% se-
quence similarity with ALR2 [11,12]. Similar to other members
of the AKR family, AKR1B10 can reduce a variety of aldehydes
and ketones [11,12]. Although, studies suggest that AKR1B10lsevier B.V. All rights reserved.
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function remains still unclear.
We have previously reported ARI activity contained in a few
spice/dietary sources prevented diabetic complications using
in vitro, ex vivo and animal models [13–17]. Curcumin was effec-
tive in delaying streptozotocin (STZ)-induced diabetic cataract in
rats mainly through its antioxidant property and inhibition of rat
lens ALR2 [14]. Subsequently, Du et al. have also reported that cur-
cumin and its synthetic analogues inhibit bovine lens ALR2 [18].
However, mechanism of inhibition, speciﬁcity with other AKRs
and its functional signiﬁcance has not been reported. In the present
study we have characterized the inhibition of human recombinant
ALR2 by curcumin and have provided insights into the nature of
inhibition. Further, we have investigated the speciﬁcity of curcu-
min towards two closely-related AKRs and its effects on intracellu-
lar sorbitol accumulation in red blood cells (RBC) under ex vivo
high glucose conditions.2. Materials and methods
2.1. Materials
D-Glucose, DL-glyceraldehyde, lithium sulfate, 2-mercap-
toethanol, NADPH, NADP, dimethyl sulfoxide (DMSO), sorbitol,
curcumin, glycine, methyl orange, perchloric acid, ammonium sul-
fate, DEAE-cellulose, Tris–HCl, EDTA, sucrose and sorbitol dehydro-
genase were purchased from Sigma Chemicals Company (St. Louis,
MO). All other chemicals were obtained from local companies.
2.2. Expression and puriﬁcation of recombinant human ALR2
Recombinant human ALR2was over-expressed inEscherichia coli
and puriﬁed from bacterial cultures essentially as described previ-
ously [19] with a minor modiﬁcation. Chromatography over AfﬁGel
Blue (Bio-Rad) afﬁnity matrix was used as a ﬁnal puriﬁcation step.
2.3. Expression and puriﬁcation of human AKR1B10
AKR1B10 was produced by over-expression from the pET23
plasmid vector containing cDNA encoding the enzyme. Puriﬁcation
from E. coli strain BL21 expression cultures was carried out as de-
scribed [10]. Puriﬁcation steps included column chromatography
over MacroQ ion exchange and AfﬁGel Blue dye afﬁnity media
essentially as described previously [19].
2.4. Puriﬁcation of ALR1 from bovine kidney
ALR1 was partially puriﬁed from bovine kidney following the
previously described methods [17,20]. Brieﬂy, freshly obtained bo-
vine kidney was homogenized in 3 vol. of 10 mM sodium phos-
phate buffer, pH 7.2 containing 0.25 M sucrose, 2.0 mM EDTA,
2.5 mM 2-mercaptoethanol. The homogenate was centrifuged at
16 000g for 20 min and the supernatant was subjected to ammo-
nium sulfate precipitation. Precipitate obtained between 45% and
75% saturation was dissolved in the above buffer and dialyzed
extensively against the same buffer. DEAE-52 resin was added to
the dialyzed material and then removed by centrifugation. The
supernatant was used as the source of ALR1.
2.5. ALR2 assay
The activity of ALR2 was measured as described previously [13].
The change in the absorbance at 340 nm due to NADPH oxidation
was followed in a Lamda35 spectrophotometer (Perkin–Elmer,
Shelton, USA).2.6. AKR1B10 assay
The activity of AKR1B10 was measured by following the rate of
oxidation of NADPH at 340 nm [10]. The assay mixture in 1 ml con-
tained 50 mM potassium phosphate buffer, pH 7.0, 0.5 mM EDTA,
20 mM glyceraldehyde, 0.15 mM NADPH and enzyme. Reaction
mixture without enzyme served as blank.
2.7. ALR1 assay
The activity of ALR1was measured spectrophotometrically by
monitoring the oxidation of NADPH at 340 nm as a function of time
at 37 C using glyceraldehyde as substrate [17]. The assay mixture
in 1 ml contained 50 mM sodium phosphate buffer of pH 7.2, 0.2 M
ammonium sulfate, 10 mM DL-glyceraldehyde, 5 mM b-mercap-
toethanol and 0.1 mM NADPH.
2.8. Inhibition studies
For inhibition studies concentrated stocks of curcumin prepared
in DMSO were used and the ﬁnal concentration of DMSO was not
more than 1%. Various concentrations of curcumin were added to
assay mixtures of ALR2, ALR1 or AKR1B10 and incubated for
5 min before initiating the reaction by NADPH as described above.
The percentage inhibition was calculated considering the activity
in the absence of curcumin as 100%. The IC50 values were deter-
mined by non-linear regression analysis of the plot of percent inhi-
bition versus log inhibitor concentration.
2.9. Enzyme kinetics
Km and Vmax of recombinant ALR2 were determined with vary-
ing concentrations of glyceraldehyde as substrate in the absence
and presence of different concentrations of curcumin by Linewe-
aver–Burk double reciprocal plots. Inhibitory constant (Ki) was de-
rived by plotting slopes obtained from Lineweaver–Burk plots
versus curcumin concentration.
2.10. In vitro incubation of RBC
Five milliliters of blood was collected into heparinized tubes
from healthy male volunteers after an overnight fast. Red blood
cells were separated by centrifugation and washed three times
with isotonic saline at 4 C. Washed RBCs were suspended in
Kreb’s-ringer bicarbonate buffer, pH 7.4 (pre-equilibrated with
5% CO2). Duplicate samples were incubated at 37 C in the presence
of 5% CO2 for 3 h under normal (5.5 mM) and high glucose (55 mM)
conditions [17]. The effect of curcumin (25–100 lM) on sorbitol
accumulation was evaluated by incubating the RBC with different
concentrations of curcumin.
2.11. Estimation of sorbitol in RBC
At the end of the incubation period, RBCs were homogenized in
9 vol of 0.8 M perchloric acid. The homogenate was centrifuged at
5000g at 4 C for 10 min and the pH of the supernatant was ad-
justed to 3.5 with 0.5 M potassium carbonate. The sorbitol content
of the supernatant was measured by a ﬂuorometric method as de-
scribed previously [21] using a spectroﬂuorometer (Jasco-FP-
6500).
2.12. Molecular docking
Molecular docking studies were done by SYBYL FlexX software
(Tripos). Ligand structures were constructed and minimized using
the SYBYL modeling program. The FlexX module in SYBYL 7.0 was
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graphic structures, which was deﬁned as all residues within 6.5 Å
away from the inhibitor in original complex by using an incremen-
tal construction algorithm. For docking studies coordinates of crys-
tal structure of proteins (ALR1: PDB # 2Ao0 and ALR2: PDB #
1PWM,) were taken from Brookhaven Protein Data Bank (PDB).
The predicted protein ligand complexes were optimized and
ranked according to the empirical scoring function ScreenScore,
which estimates the binding free energy of the ligand receptor
complex [22,23].
3. Results and discussion
The beneﬁcial effect of ARI in preventing or delaying the onset
of diabetic complications in experimental models provides a strong
support to the hypothesis that ALR2 inhibition could be an effec-
tive strategy in the prevention or delay of certain diabetic compli-
cations. However, studies with ARI have yielded inconsistent
results in experimental animals and also in clinical trials to assess
efﬁcacy against various diabetic complications [5,7,24,25]. In addi-
tion to its antioxidant property, we observed a lowered activity of
ALR2 in curcumin fed diabetic rat lens compared to untreated dia-
betic rat lens [14], indicating that possibility of inhibition of ALR2
by curcumin. In the current study we demonstrate by in vitro as-
says that curcumin inhibits ALR2 directly. Further, we probed the
mechanism of inhibition and speciﬁcity toward ALR2 as comparedFig. 1. Inhibition of ALR2 and AKR1B10 by curcumin. (Panel A) Representative
inhibition curve of human recombinant ALR2 by curcumin. (Panel B) Representative
inhibition curve of human AKR1B10 by curcumin. ALR2 and AKR1B10 activity in the
absence of curcumin was considered as 100%. Data are average of three indepen-
dent experiments.with other members of the AKR family. To test for physiological
signiﬁcance, we measured the ability of curcumin to block ALR2
activity in freshly harvested human erythrocytes.
Curcumin inhibited human recombinant ALR2 with an IC50 of
10.0 ± 4.0 lM (Fig. 1A). The primary structure of ALR2 displays
high similarities with aldehyde reductase (ALR1) and human small
intestine reductase (HSIR, AKR1B10), closely-related members of
the aldo-keto reductase superfamily. ALR1 and ALR2 both catalyze
the reduction of biogenic aldehydes, and all the three AKRs cata-
lyze the NADPH-dependent reduction of a variety of carbonyls
such as glyceraldehye, glucuronate, and short chain alkanals [10–
12]. Because many active site residues including Tyr-49, His-111,
Cys-299, Trp-21, Phe-123 that are important in inhibitor interac-
tions are the same in ALR2 and AKR1B10 [26], it is not surprising
that many compounds known to inhibit ALR2 such as tolrestat,
sorbinil and fenoﬁbrates also inhibit AKR1B10 [27]. Therefore, we
studied the speciﬁcity of curcumin with these two related AKR
members. Though curcumin inhibited AKR1B10 (Fig. 1B), the IC50
value was three times higher than ALR2 (30.0 ± 3.0 lM), indicating
its relative selectivity for ALR2. It was interesting to note that cur-
cumin did not inhibit bovine kidney ALR1 up to 200 lM concentra-
tion under the conditions employed in the study (data not shown),
signifying its marked speciﬁcity towards ALR2 over ALR1. Next we
determined some kinetic parameters such as Km and Vmax to under-
stand the mechanism of inhibition of ALR2 by curcumin. In the
presence of different concentrations of curcumin, Vmax wasFig. 2. Kinetics of human recombinant aldose reductase inhibition. (Panel A)
Lineweaver–Burk plot of recombinant ALR2 in the absence and presence of various
concentration of curcumin. Final concentrations of curcumin used in the assay
system: ‘0’ (circles), 10 (triangles), 30 (diamond) and 45 lM (hexagonal). (Panel B)
Determination of inhibitory constant (Ki). Slopes of the Lineweaver–Burk plot were
plotted as a function of curcumin concentration and X-axis intercept of this plot
gives Ki. Data in Panel A and B are average of three independent experiments.
Table 1
Kinetics of human recombinant ALR2 in the absence and presence of curcumin. Data
are the means ± S.E. (n = 6). Vmax is reported as lmoles NADPH oxidized/min/mg
protein.
Curcumin (lM) Km (mM) Vmax
‘0’ 0.232 ± 0.08 0.074 ± 0.019
10 0.243 ± 0.07 0.045 ± 0.011
30 0.240 ± 0.05 0.034 ± 0.014
45 0.244 ± 0.11 0.022 ± 0.013
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substrate (Fig. 2A and Table 1). These results suggested a non-com-
petitive inhibition of ALR2 by curcumin. Further, we have deter-
mined inhibitory constant (Ki) from the secondary plots of
Lineweaver–Burk plots and Ki of curcumin for ALR2 was found toFig. 3. Stereoviews of ALR2 and ALR1 docked with curcumin. (Panel A) Curcumin (keto fo
Trp-20, His-110, Trp-111, Leu-300, Leu-301, Ile-260 and nicotinamide ring. (Panel B) Cur
mainly with residues Tyr-50, Lys-80, Gln-184, Ser-215, Lys-263, Ser-264, Thr-266 and
dashed yellow lines.be 40  106 M (Fig. 2B). As reported by Bohren et al. [28],
although many ionic inhibitors bind to active site, still show non-
competitive to uncompetitive pattern inhibition because under
steady-state conditions most of the enzyme will be present as en-
zyme–nucleotide binary complex. Hence, compounds that selec-
tively bind to the enzyme–nucleotide complex are more effective
than those bind to free enzyme.
Thus, molecular docking studies were conducted to substanti-
ate the binding pattern and selective inhibition of ALR2 by curcu-
min. It was observed that curcumin likely interacts with ALR2 at
active site residues Tyr-48, Lys-21, Thr-19 and Gln-183 (hydrogen
bond distance 2.90, 2.03, 2.96 and 2.43 Å). Further, there was
hydrogen bonding with Leu-300 and Trp-111 (distance 2.70 and
2.22 Å, respectively). Hence, it appears that curcumin might bind
to ALR2 in a closed type of conformation (Fig. 3A). In case of
ALR1, hydrogen bonding was observed between curcumin andrm) docked into active site of ALR2 and depicts its interaction with residues Thr-19,
cumin (keto form) docked into active site of ALR1. In this case curcumin interacted
Arg-269 but no interaction with Val-300 and Pro-301. Hydrogen bonds shown in
Fig. 5. Effect of curcumin on sorbitol accumulation in RBC. Sorbitol levels in RBC
under normal glucose concentration (5.5 mM) (bar 1) under high glucose (55 mM)
conditions in the absence (bar 2) and presence of 25 lM, 50 lM and 100 lM
curcumin (bars 3–5, respectively). Data are means ± S.E. (n = 6).
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2.01, 2.02 and 2.50 Å) (Fig. 3B). Since Leu-300 and Leu-301 are re-
placed by Pro-300 and Val-301 in ALR1, curcumin did not interact
with Pro-300 and Val-301. It is interesting to note that unlike with
ALR1, curcumin interacted with Leu-300 and Leu-301 in ALR2 that
are involved in imparting plasticity to ALR2. Because of these spe-
ciﬁc interactions curcumin could inhibit ALR2 but not ALR1. Simi-
lar interaction of ﬁdarestat with ALR2 was implicated for its
speciﬁcity towards ALR2 over ALR1 [29]. These observations indi-
cate that curcumin could be a speciﬁc inhibitor of ALR2. Aromatic
phenol rings of curcumin are connected by two a,b-unsaturated
carbonyl groups and exhibits keto-enol tautomerization through
an enolate intermediate (Fig. 4). Curcumin predominantly exists
as a keto form under the neutral pH conditions employed in this
study for inhibition assays. Though, we have performed molecular
docking studies with both keto and enol forms and the results were
similar with both the forms, for simplicity, we showed molecular
docking data with keto form (Fig. 3).
Compared with some potent ARI (ﬁdarestat), the IC50 value ob-
tained with curcumin (10 lM) was modest. However, the relative
speciﬁcity shown by curcumin towards human ALR2 over other
AKRs, particularly ALR1, underscores its importance in terms of
achieving good inhibition of ALR2 without side effects related to
off-target inhibition of ALR1. In addition, the data also suggest that
curcumin might aid in guiding the development or identiﬁcation of
highly speciﬁc ARIs.
Among human AKRs, ALR2 is unique in its ability to catalyze the
NADPH-dependent conversion of glucose to sorbitol [12]. In addi-
tion to lens, retina, nerve and kidney, activation of ALR2 in RBC
leads to the accumulation of sorbitol [30]. We have also found a di-
rect correlation between erythrocyte ALR2 and sorbitol levels [31].
Therefore, we assessed accumulation of sorbitol in RBC under high
glucose conditions (ex vivo) to understand the signiﬁcance of
in vitro inhibition of ALR2 by curcumin, particularly the effect of
curcumin on osmotic stress. In vitro incubation of RBC with
55 mM glucose resulted in the accumulation of sorbitol 3–4-fold
higher than the control (ANOVA P < 0.05) (Fig. 5). Incubation of
RBC in the presence of curcumin under high glucose conditions
lead to reduction in the accumulation of intracellular sorbitol in
a dose dependent manner (ANOVA P < 0.05) (Fig. 5). While there
was 50% reduction of sorbitol accumulation with 50 lM curcumin,
complete inhibition was observed with 100 lM curcumin. Further,
we found similar results with rat retinal explants cultured under
high glucose conditions in the absence and presence of 50 lM cur-
cumin (data not shown). These results not only substantiate the
inhibition of ALR2 by curcumin but also indicate the signiﬁcanceFig. 4. Two-dimensional structures of keto and enol forms of curcumin.of curcumin in terms of preventing the accumulation of intracellu-
lar sorbitol.
Although the beneﬁcial impact of strict glycemic control on pre-
vention of diabetic complications has been well established, most
individuals with diabetes rarely achieve consistent euglycemia.
Hence, agents that can substantially delay or prevent the onset
and development of diabetic complications, irrespective of glyce-
mic control, would offer many advantages. In principle, ARI can
be included in this category. Thus, intensive research continues
to identify and test both synthetic as well as natural products for
their therapeutic value to prevent the onset and/or delay progres-
sion of diabetic complications.
In conclusion, results of the present study indicate that curcu-
min inhibits human recombinant ALR2 in a non-competitive man-
ner and this inhibition appears to be relatively speciﬁc towards to
ALR2 over ALR1. Suppression of sorbitol accumulation in human
erythrocytes under high glucose conditions by curcumin is sugges-
tive of translating its impact to in vivo conditions which are sup-
ported by our previous studies that curcumin delayed the
progression of cataract and inhibited retinal VEGF expression in
STZ-induced diabetic rats [14,16]. Others also have reported the
clinical signiﬁcance curcumin on retina under diabetic/hyperglyce-
mic conditions [32,33]. Finally, these observations suggest that
curcumin or its synthetic analogues could be explored for alleviat-
ing complications of diabetes.
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